Matrix metalloproteinases, tissue inhibitors of MMPs and TACE in experimental cerebral malaria

Laboratory Investigation

Volumn 86, Issue 9, 2006, Pages 873-888

  Van Den Steen, Philippe E ^a   Van Aelst, Ilse ^a   Starckx, Sofie ^a   Maskos, Klaus ^b   Opdenakker, Ghislain ^a   Pagenstecher, Axel ^c  

^a REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

^b MAX PLANCK INSTITUTE OF BIOCHEMISTRY   (Germany)

^c PHILIPPS UNIVERSITY MARBURG   (Germany)

Author keywords

Cerebral malaria; Gelatinase; Matrix metalloproteinase; Plasmodium berghei ANKA; RT PCR; Zymography

Indexed keywords

COLLAGENASE 3; GELATINASE B; MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE 14; NEUTROPHIL COLLAGENASE; STROMELYSIN; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN MALARIA; CONTROLLED STUDY; DISEASE PREDISPOSITION; ENDOTHELIUM CELL; ENZYME ACTIVATION; MOLECULAR EVOLUTION; MOUSE; NONHUMAN; PLASMODIUM BERGHEI; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ADAM PROTEINS; ANIMALS; ANTIGENS, CD11B; BRAIN; ELECTROPHORESIS; GENE EXPRESSION; MALARIA, CEREBRAL; MATRIX METALLOPROTEINASES; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; PHENYLALANINE; PLASMODIUM BERGHEI; THIOPHENES; TISSUE INHIBITOR OF METALLOPROTEINASES;

EID: 33747603432     PISSN: 00236837     EISSN: 15300307     Source Type: Journal    
DOI: 10.1038/labinvest.3700454     Document Type: Article

References (61)

1. Gardner MJ, Hall N, Fung E, et al. Genome sequence of the human malaria parasite Plasmodium falciparum. Nature 2002;419:498-511.
2. Holt RA, Subramanian GM, Halpern A, et al. The genome sequence of the malaria mosquito Anopheles gambiae. Science 2002;298:129-149.
3. de Souza JB, Riley EM. Cerebral malaria: the contribution of studies in animal models to our understanding of immunopathogenesis. Microbes Infect 2002;4:291-300.
4. Sexton AC, Good RT, Hansen DS, et al. Transcriptional profiling reveals suppressed erythropoiesis, up-regulated glycolysis, and interferon-associated responses in murine malaria. J Infect Dis 2004;189:1245-1256.
5. Schofield L, Grau GE. Immunological processes in malaria pathogenesis. Nat Rev Immunol 2005;5:722-735.
6. Hunt NH, Grau GE. Cytokines: accelerators and brakes in the pathogenesis of cerebral malaria. Trends Immunol 2003;24:491-499.
7. Wassmer SC, Lepolard C, Traore B, et al. Platelets reorient Plasmodium falciparum-infected erythrocyte cytoadhesion to activated endothelial cells. J Infect Dis 2004;189:180-189.
8. Pino P, Vouldoukis I, Kolb JP, et al. Plasmodium falciparum-infected erythrocyte adhesion induces caspase activation and apoptosis in human endothelial cells. J Infect Dis 2003;187:1283-1290.
9. Adams S, Brown H, Turner G. Breaking down the blood-brain barrier: signaling a path to cerebral malaria? Trends Parasitol 2002;18:360-366.
10. Penet MF, Viola A, Confort-Gouny S, et al. Imaging experimental cerebral malaria in vivo: significant role of ischemic brain edema. J Neurosci 2005;25:7352-7358.
11. Amani V, Vigario AM, Belnoue E, et al. Involvement of IFN-gamma receptor-medicated signaling in pathology and anti-malarial immunity induced by Plasmodium berghei infection. Eur J Immunol 2000;30:1646-1655.
12. Grau GE, Heremans H, Piguet PF, et al. Monoclonal antibody against interferon gamma can prevent experimental cerebral malaria and its associated overproduction of tumor necrosis factor. Proc Natl Acad Sci USA 1989;86:5572-5574.
13. Engwerda CR, Mynott TL, Sawhney S, et al. Locally up-regulated lymphotoxin alpha, not systemic tumor necrosis factor alpha, is the principle mediator of murine cerebral malaria. J Exp Med 2002;195:1371-1377.
14. Lucas R, Juillard P, Decoster E, et al. Crucial role of tumor necrosis factor (TNF) receptor 2 and membrane-bound TNF in experimental cerebral malaria. Eur J Immunol 1997;27:1719-1725.
15. Gimenez F, Barraud DL, Fernandez C, et al. Tumor necrosis factor alpha in the pathogenesis of cerebral malaria. Cell Mol Life Sci 2003;60:1623-1635.
16. Nitcheu J, Bonduelle O, Combadiere C, et al. Perforin-dependent brain-infiltrating cytotoxic CD8+ T lymphocytes mediate experimental cerebral malaria pathogenesis. J Immunol 2003;170:2221-2228.
17. Chang WL, Jones SP, Lefer DJ, et al. CD8(+)-T-cell depletion ameliorates circulatory shock in Plasmodium berghei-infected mice. Infect Immun 2001;69:7341-7348.
18. Belnoue E, Kayibanda M, Vigario AM, et al. On the pathogenic role of brain-sequestered alphabeta CD8+ T cells in experimental cerebral malaria. J Immunol 2002;169:6369-6375.
19. Nagase H, Woessner JF. Matrix metalloproteinases. J Biol Chem 1999;274:21491-21494.
20. Parks WC, Wilson CL, Lopez-Boado YS. Matrix metalloproteinases as modulators of inflammation and innate immunity. Nat Rev Immunol 2004;4:617-629.
21. Gursoy-Ozdemir Y, Qiu J, Matsuoka N, et al. Cortical spreading depression activates and upregulates MMP-9. J Clin Invest 2004;113:1447-1455.
22. Mun-Bryce S, Rosenberg GA. Gelatinase B modulates selective opening of the blood-brain barrier during inflammation. Am J Physiol 1998;274:R1203-R1211.
23. Yong VW, Power C, Forsyth P, et al. Metalloproteinases in biology and pathology of the nervous system. Nat Rev Neurosci 2001;2:502-511.
24. Opdenakker G, Van den Steen PE, Van Damme J. Gelatinase B: a tuner and amplifier of immune functions. Trends Immunol 2001;22:571-579.
25. Van den Steen PE, Dubois B, Nelissen I, et al. Biochemistry and molecular biology of gelatinase B or matrix metalloproteinase-9 (MMP-9). Crit Rev Biochem Mol Biol 2002;37:375-536.
26. Asahi M, Asahi K, Jung JC, et al. Role for matrix metalloproteinase 9 after focal cerebral ischemia: effects of gene knockout and enzyme inhibition with BB-94. J Cereb Blood Flow Metab 2000;20:1681-1689.
27. Asahi M, Wang X, Mori T, et al. Effects of matrix metalloproteinase-9 gene knock-out on the proteolysis of blood-brain barrier and white matter components after cerebral ischemia. J Neurosci 2001;21:7724-7732.
28. Prato M, Giribaldi G, Polimeni M, et al. Phagocytosis of hemozoin enhances matrix metalloproteinase-9 activity and TNF-alpha production in human monocytes: role of matrix metalloproteinases in the pathogenesis of falciparum malaria. J Immunol 2005;175:6436-6442.
29. Gearing AJ, Beckett P, Christodoulou M, et al. Processing of tumour necrosis factor-α precursor by metalloproteinases. Nature 1994;370:555-557.
30. Gearing AJH, Beckett P, Christodoulou M, et al. Matrix metalloproteinases and processing of pro-TNF-α. J Leukoc Biol 1995;57:774-777.
31. Black RA, Rauch CT, Kozlosky CJ, et al. A metalloproteinase disintegrin that releases tumour-necrosis factor-alpha from cells. Nature 1997;385:729-733.
32. Moss ML, Jin SL, Milla ME, et al. Cloning of a disintegrin metalloproteinase that processes precursor tumour-necrosis factor-alpha. Nature 1997;385:733-736.
33. Sullivan AD, Ittarat I, Meshnick SR. Patterns of haemozoin accumulation in tissue. Parasitology 1996;112(Part 3):285-294.
34. Pagenstecher A, Stalder AK, Campbell IL. RNAse protection assays for the simultaneous and semiquantitative analysis of multiple murine matrix metalloproteinase (MMP) and MMP inhibitor mRNAs. J Immunol Methods 1997;206:1-9.
35. Descamps FJ, Martens E, Opdenakker G. Analysis of gelatinases in complex biological fluids and tissue extracts. Lab Invest 2002;82:1607-1608.
36. Masure S, Billiau A, Van Damme J, et al. Human hepatoma cells produce an 85 kDa gelatinase regulated by phorbol 12-myristate 13-acetate. Biochim Biophys Acta 1990;1054:317-325.
37. Pagenstecher A, Stalder AK, Kincaid CL, et al. Regulation of matrix metalloproteinases and their inhibitor genes in lipopolysaccharide-induced endotoxemia in mice. Am J Pathol 2000;157:197-210.
38. Oh LYS, Larsen PH, Krekoski CA, et al. Matrix metalloproteinase-9/ gelatinase B is required for process outgrowth by oligodendrocytes. J Neurosci 1999;19:8464-8475.
39. Opdenakker G, Van den Steen PE, Dubois B, et al Gelatinase B functions as regulator and effector in leukocyte biology. J Leukocyte Biol 2001;69:851-859.
40. Dubois B, Masure S, Hurtenbach U, et al. Resistance of young gelatinase B-deficient mice to experimental autoimmune encephalomyelitis and necrotizing tail lesions. J Clin Invest 1999;104:1507-1515.
41. Dubois B, Starckx S, Pagenstecher A, et al. Gelatinase B deficiency protects against endotoxin shock. Eur J Immunol 2002;32:2163-2171.
42. Murphy G, Willenbrock F. Tissue inhibitors of matrix metalloendopeptidases. Methods Enzymol 1995;248:496-510.
43. Amour A, Hutton M, Knauper V, et al. Inhibition of the metalloproteinase domain of mouse TACE. Ann NY Acad Sci 1999;878:728-731.
44. Li YY, Kadokami T, Wang P, et al. MMP inhibition modulates TNF-alpha transgenic mouse phenotype early in the development of heart failure. Am J Physiol Heart Circ Physiol 2002;282:H983-H989.
45. D'Haese A, Wuyts A, Dillen C, et al. In vivo neutrophil recruitment by granulocyte chemotactic protein-2 is assisted by gelatinase B/MMP-9 in the mouse. J Interferon Cytokine Res 2000;20:667-674.
46. Kolaczkowska E, Scislowska-Czarnecka A, Chadzinska M, et al. Enhanced early vascular permeability in gelatinase B (MMP-9)-deficient mice: putative contribution of COX-1-derived PGE2 of macrophage origin. J Leukoc Biol 2006;80:125-132.
47. Deininger MH, Winkler S, Kremsner PG, et al. Angiogenic proteins in brains of patients who died with cerebral malaria. J Neuroimmunol 2003;142:101-111.
48. Van Lint P, Wielockx B, Puimege L, et al. Resistance of collagenase-2 (matrix metalloproteinase-8)-deficient mice to TNF-induced lethal hepatitis. J Immunol 2005;175:7642-7649.
49. Wielockx B, Lannoy K, Shapiro SD, et al. Inhibition of matrix metalloproteinases blocks lethal hepatitis and apoptosis induced by tumor necrosis factor and allows safe antitumor therapy. Nat Med 2001;7:1202-1208.
50. Tan RJ, Fattman CL, Niehouse LM, et al. Matrix metalloproteinases promote inflammation and fibrosis in asbestos-induced Lung Injury in Mice. Am J Respir Cell Mol Biol 2006, in press [Epub ahead of print].
51. Lee MM, Yoon BJ, Osiewicz K, et al. Tissue inhibitor of metalloproteinase 1 regulates resistance to infection. Infect Immun 2005;73:661-665.
52. McClellan SA, Huang X, Barrett RP, et al. Matrix metalloproteinase-9 amplifies the immune response to Pseudomonas aeruginosa corneal infection. Invest Ophthalmol Vis Sci 2006;47:256-264.
53. Turner GD, Morrison H, Jones M, et al. An immunohistochemical study of the pathology of fatal malaria. Evidence for widespread endothelial activation and a potential role for intercellular adhesion molecule-1 in cerebral sequestration. Am J Pathol 1994;145:1057-1069.
54. Pilcher BK, Wang M, Qin X-J, et al. Role of matrix metalloproteinases and their inhibition in cutaneous wound healing and allergic contact hypersensitivity. Ann NY Acad Sci 1999;878:12-24.
55. Larsen PH, Wells JE, Stallcup WB, et al. Matrix metalloproteinase-9 facilitates remyelination in part by processing the inhibitory NG2 proteoglycan. J Neurosci 2003;23:11127-11135.
56. Powell WC, Fingleton B, Wilson CL, et al. The metalloproteinase matrilysin proteolytically generates active soluble Fas ligand and potentiates epithelial cell apoptosis. Curr Biol 1999;9:1441-1447.
57. Schönbeck U, Mach F, Libby P. Generation of biologically active IL-1β by matrix metalloproteinases: a novel caspase-1-independent pathway of IL-1β processing. J Immunol 1998;161:3340-3346.
58. Sheu BC, Hsu SM, Ho HN, et al. A novel role of metalloproteinase in cancer-mediated immunosuppression. Cancer Res 2001;61:237-242.
59. Van den Steen PE, Proost P, Wuyts A, et al. Neutrophil gelatinase B potentiates interleukin-8 tenfold by aminoterminal processing, whereas it degrades CTAP-III, PF-4, and GRO-alpha and leaves RANTES and MCP-2 intact. Blood 2000;96:2673-2681.
60. McQuibban GA, Gong JH, Tam EM, et al. Inflammation dampened by gelatinase A cleavage of monocyte chemoattractant protein-3. Science 2000;289:1202-1206.
61. Murata CE, Goldberg DE. Plasmodium falciparum falcilysin: a metalloprotease with dual specificity. J Biol Chem 2003;278:38022-38028.